Everolimus and temsirolimus have been used as mTOR inhibitors and are approved for the treatment of breast cancer, renal cell carcinoma, and pancreatic neuroendocrine tumors [20,21,22]. This evidence concerns the gene MTOR and hereditary clear cell renal cell carcinoma.